The clinical diagnosis of schizophrenia is primarily based on the DSM-5, and the ICD-11. The two models are based on the existence and duration of typical symptoms, which include hallucinations, delusions, disorganized speech or behavior, and negative symptoms such as emotional flattening or avolition, and high-level functional impairment [9]. The DSM-5 states that the diagnosis must include two or more of these symptoms lasting at least one month, with persistent signs of disturbance for at least six months, as defined by the American Psychiatric Association (APA). Similarly, ICD-11 describes schizophrenia based on persistent psychotic symptoms over time while emphasizing that symptom assessment should be interpreted within the individual’s cultural and clinical context [10].

Although these criteria provide a standardized psychiatric classification framework, their symptom-oriented nature introduces subjectivity and may contribute to inter-rater variability and diagnostic inconsistency, particularly during prodromal or early-stage presentations. A meta-analysis study found that diagnostic concordance rates in first-episode psychosis can range from 60–70 percent between clinicians, mainly because of similarity with other neuropsychiatric disorders including bipolar disorder, schizophrenic disorder, and major depression with psychotic characteristics [3].

Moreover, currently, no validated biological or molecular markers of schizophrenia are used in diagnostic lists. This lack of objective tools helps to further prolong the diagnosis process, which usually takes one to three years since the onset of the symptoms, a critical period in which early intervention may significantly benefit the outcome at the end of the process [3]. Adding to this problem is the fact that there is also a phenomenon known as diagnostic migration where initial clinical diagnosis of the patient changes dramatically with time, usually because of the varying progression of symptoms and developing cognitive or functional impairments [11].

The issue goes beyond initial diagnosis to forecast progression and response to treatment of the disease. Although antipsychotic treatment is effective in positive symptoms among most patients, the effect of antipsychotics on negative symptoms and cognitive impairments is inconsistent. However, the existing diagnostic methods do not give much predictive information on treatment pathways, probability of response or risk of relapse, which are imperative to plan patient care at the individual level [12].

The inability to convert the neuroimaging, electrophysiological, and genomic findings into the clinical instruments is a major bottleneck as the research in these fields evolves. Neurobiological investigations like the ENIGMA Schizophrenia Consortium have repeatedly reported structural and functional brain dysfunctions like hippocampal volume and dysregulated prefrontal connections with the condition [13]. Nevertheless, the translation of such findings into diagnostic utility has remained elusive, in part because of the complexity and high dimensionality of such data, and the absence of powerful analytical frameworks that can be used to produce useful insights [14].

The diagnostic gap identified by this diagnostic opacity demonstrates a severe weakness within the existing work of psychiatry: the necessity of instruments with predictive capabilities, objectivity, and scalability. AI presents a very promising opportunity to solve this deficiency. Through the use of ML algorithms to predict and process complex multimodal data such as neuroimaging, voice records, genetic profiles, and behavioral markers AI can help to create measurable and personalized diagnostic signatures. These improvements have the potential to reduce the untreated psychosis (DUP) period, better stratify risk, and assist in the setting of the individualized therapy approach at its very beginning [15].

Contemporary developments in AI have substantially expanded the field of psychiatric diagnostics. Schizophrenia is a complex and heterogeneous disorder of cognitive, behavioral, and neurobiological functions that is an interesting opportunity for AI-enabled precision medicine [16]. The increased access to multi-modal data, including speech, neuroimaging, electrophysiology, and omics, has enabled data-driven insights that extend beyond conventional clinical models and existing diagnostic paradigms [17]. In this section, the four main areas in which AI is transforming the diagnostics of schizophrenia have been critically examined and they are NLP, neuroimaging analysis, electrophysiological modeling, and multi-omics integration [18]. Figure 1 describes the multi-modal AI workflow in order to visualize the structure of the integrated diagnostic tools. It shows how NLP, neuroimaging, electrophysiological modeling, and multi-omics data can be united in ML models to improve the detection and stratification of schizophrenia in the early phases of the disorder.

While AI-based diagnostic paradigms have shown great potential, there is variability in terms of their clinical utility depending on the type of data. NLP-based paradigms are relatively easy to scale and cost-efficient since vocal recordings can be done remotely. However, there are limitations to their reliability, such as language, culture, education, and transcription quality. Neuroimaging-based paradigms provide extensive biological insights and detect structural and functional deviations that can lead to schizophrenia. Nevertheless, they are limited in widespread clinical application due to financial constraints, limited scanner access, data standardization, and external validity [13]. EEG and magnetoencephalography (MEG)-based paradigms are more mobile and time-sensitive, but signal noise and reproducibility of biomarkers need to be addressed. Finally, multi-omics models help understand heterogeneous pathophysiology and drug response in patients but rely heavily on annotated data and are not easily implementable in psychiatric practice. Thus, the most clinically useful strategy might not involve any single AI technology but rather multimodal AI models with careful validation and implementation [15].

Even though oral antipsychotics continue to be the main modality of schizophrenia treatment, traditional preparations have numerous pharmacological and clinical deficiencies that compromise success in the long-term treatment of the condition [37]. These constraints are multifactorial- they include issues with pharmacokinetics, central nervous system (CNS) targeting, patient compliance as well as systemic side effects. These limitations highlight the need for more intelligent, flexible, and patient-centered oral drug delivery approaches [37, 38].

Limitations of traditional oral antipsychotics are not applicable to all medicines; rather, they vary depending on physicochemical and pharmacokinetic properties of each medicine. Second-generation antipsychotics, including risperidone, olanzapine, and quetiapine, show differences in aqueous solubility, first-pass metabolism, cytochrome P450 (CYP) enzyme-mediated metabolic pathways, oral bioavailability, and efflux mechanisms involving P-glycoprotein (P-gp). Such differences affect pharmacokinetics of the drugs, which determines the efficiency of therapy, dosing schedule, variations in efficacy, and possibility of interactions. Hence, a comparative analysis of drugs can be valuable in order to determine what kind of pharmacokinetic obstacles can be resolved using nanoformulation and AI.

The drug-specific pharmacokinetic limitations of representative oral antipsychotics are summarized in Table 2, emphasizing solubility, first-pass metabolism, CYP pathways, oral bioavailability, and P-gp-related barriers. It becomes evident from this analysis that the requirement for an advanced formulation system for oral delivery depends on the characteristics of each drug. For risperidone, the two major obstacles to overcome besides systemic absorption are the CYP2D6 variability and the P-gp effect on its entry into the brain. Olanzapine’s insufficient water solubility and extensive first-pass metabolism in the liver call for the application of lipid-based, amorphous, and nanosized formulations to improve solubility and eliminate pharmacokinetic variability. The extremely low bioavailability due to extensive CYP3A4 metabolism is a major argument in favor of advanced delivery for quetiapine. This also affects the complexity of the implementation of AI approaches. If the parameters of a drug formulation are defined, including the particle size, the rate of dissolution, and entrapment efficiency, the drug is a good fit for AI optimization. When transporter activity, genotype, and brain entry are considered, the data are more complex.

Extensive first-pass metabolism is one of the greatest pharmacokinetic barriers. Various commonly used second generation antipsychotics, including risperidone, quetiapine, or olanzapine, are greatly hepatically transformed by CYP enzymes, especially CYP2D6 and CYP3A4. This metabolic clearance can substantially reduce oral bioavailability and may require higher oral doses to achieve therapeutic plasma concentrations [39]. Such high dose level increases the risk of systemic toxicity, and also leads to the broad interpatient ranges in drug exposure because of genetic polymorphisms in the metabolic enzymes.

In addition, there are other obstacles to ideal absorption in the gastrointestinal (GI) environment. Isolubility of the drug depends on pH, emptying of the stomach varies, and the efflux transporters found in the intestinal epithelia are some of the factors that make pharmaceutical absorption unpredictable. The lipophilic antipsychotics often have low aqueous solubility that limits their solubility in the gastric lumen. For example, the dissolution and absorption of poorly water-soluble antipsychotics may be affected by gastrointestinal pH changes, gastric emptying variability, and proton pump inhibitor use, particularly in older adults [40]. These not only interfere with the pharmacokinetic profile but also make the design of formulation and dosing more difficult.

The fact that the conventional oral formulations have a low capacity to guarantee effective delivery of CNS is an equally problematic issue. The blood-brain barrier (BBB) is a very selective physiologic interface that helps to limit the passage of most therapeutic agents into brain parenchyma. The majority of antipsychotics are dependent on passive diffusion, and additional inhibitors include the efflux proteins like the P-gp that actively deliver drugs out of the CNS. These transporters have been reported to be upregulated in patients with schizophrenia and this may be one of the reasons as to why they are resistant to treatment [41]. Consequently, despite adequate plasma levels, brain concentrations may remain below therapeutic levels, thereby limiting clinical efficacy and necessitating higher doses.

Clinically, low compliance has continued to be one of the problems of schizophrenia treatment. Cognitive disabilities, poor insight, and avolition may all minimise the chances of regular oral medication taking. It has been observed that oral antipsychotic therapy is discontinued by almost 60 percent of patients during the first year of study and most times not under the advice of a medical professional [42]. The result of this discontinuation is high rates of relapse, hospitalization and total healthcare burden. Besides, non-targeted systemic distribution side effects like sedation, weight gain, hyperprolactinemia, and metabolic syndrome further reduce adherence and patient confidence in treatment.

The other major shortcoming is the strict pharmacokinetic characteristics of traditional oral formulations. Fixed release tablets or capsules lack the flexibility to address the reality of differences between metabolism, circadian variation and comorbidities. They also have a low flexibility in relation to time release or location specificity, which are essential in directing treatment to vulnerable groups, such as the ageing or patients with gastro intestinal comorbidities [43].

All these constraints highlight how insufficient the existing system of oral delivery is to address the generalized needs of schizophrenia therapy in the long term. More advanced methods are necessary because it is evident in clear platforms that could be able to improve the targeting of the CNS and bioavailability, besides alleviating the ill effects and aiding compliance. This clinical need has led to the renewed interest in nanotechnology-based responsive and patient-centric drug delivery systems that are discussed in the next section [44].

In a bid to curb the natural drawbacks of traditional antipsychotic preparations, recent studies have been directed towards development of nanotechnology-based oral drug delivery systems. These systems improve the dissolution, stability, and delivery specificity of antipsychotic drugs that provide regulated release profiles and higher CNS bioavailability [45]. Various systems have been proposed to be used in schizophrenia therapy, such as lipid-based nanoparticles, polymeric carriers, proliposomes, stimuli-responsive, and ligand-targeted nanocarriers, which have demonstrated high potential in preclinical and early clinical trials.

The nanocarriers described in this section cannot be considered to have equivalent designs for translation. The translational success of each carrier platform is based on the physicochemical characteristics of the drug, as well as its stability in the GI environment, manufacturability, ability to increase the concentration in the brain, and compatibility with AI in formulation design. The advantages of using lipid nanocarriers include increased solubility and lymphatic uptake; nevertheless, their physical stability and lipid phase transitions may limit predictions and large-scale production [46]. Polymeric nanoparticles are advantageous when precise control over particle size, surface functionalization, and release rate are required; but they are generally harder to manufacture. Despite offering precision in terms of surface modification, dendrimers have issues linked to toxicity, high cost, and regulation difficulties. On the other hand, proliposomes and self-emulsifying drug delivery system (SEDDS) can be relatively easily modified into oral formulations and thus be more compatible with manufacturing processes. However, they might offer less biological specificity in terms of delivering drugs to the CNS without the use of other targeting methods [45]. As far as stimuli-responsive systems or ligand-targeted delivery systems are concerned, they can be considered the most biologically specific, yet they will be the most difficult systems for implementation using AI because the model would need to consider several parameters related to triggering and biological activity.

Traditional formulation development and dosing strategies in schizophrenia therapy are largely empirical and often rely on standardized protocols and fixed dosing regimens. This empirical method can not consider the patient specific variation in drug absorption, distribution, metabolism, and elimination, resulting in variable results [59]. Recent innovations in AI have provided new opportunities of precision pharmacokinetics and personalised drug delivery. Using massive amounts of data and ML algorithms, AI is facilitating the dynamic modelling of formulation properties and optimisation of dose to the patient [60].

Over the past decade, oral nanocarriers and targeted drug delivery systems have shown considerable progress in the preclinical development of schizophrenia therapeutics. Nevertheless, the ultimate measure of innovation is successful clinical translation, which has historically been limited by formulation instability, manufacturing challenges, and regulatory uncertainty [69]. Between 2022 and 2025, several advanced oral drug delivery approaches and AI-supported therapeutic strategies have progressed through preclinical evaluation, early clinical investigation, or computational validation. These studies highlight recent advances in AI-supported therapeutic strategies and targeted drug delivery systems, demonstrating encouraging progress toward clinical translation, although broader clinical confirmation remains necessary [69, 70].

Recent methods of formulating and dosing drugs in schizophrenia are still predominantly empirically based, relying on fixed-dose regimens and generalized pharmacokinetic modeling. This conventional approach does not fully account for interindividual biological variability, which can influence treatment response and therapeutic outcomes [71]. This makes therapeutic results highly variable, with side effects being unpredictable. The development of AI is an interesting solution. Based on practical data and sophisticated ML models, AI is facilitating personalized formulation modeling and dose-specific adjustments to patients to facilitate a more accurate and flexible treatment paradigm.

AI is transforming the nature of drug formulation science, which allows predicting key pharmacokinetic parameters of the drug in terms of its reaction to patient-specific variables. They are genetic polymorphisms (such as CYP450 isoenzymes), age, sex, body mass index, hepatic and renal functioning, eating habits, and co-medication records [80]. Using these data in ML models, researchers are able to predict drug absorption, bioavailability, distribution, and clearance with an unprecedented degree of accuracy. The formulation properties that can be optimized in-silico using these models include the choice of the polymer, the size of the nanoparticles, the release behavior, and the mucosal adhesion characteristics.

Tanaka multi-input ANN to predict plasma olanzapine levels depending on drug formulation, differences in genotypes, and the consumption of dietary fat. Their model had an error of less than 10% on the mean error, which enabled proper prediction of therapeutic ranges in simulated populations [80, 81]. These tools are being incorporated in formulation design platforms to minimize empirical testing and hasten the process of clinical trials of optimized nanocarriers.

Besides, AI can be used to dynamically optimize by connecting real-time physiological data (hormone levels, inflammatory markers, and circadian metrics) with drug release properties. Adaptive modeling may be used to optimize drug release characteristics and dosing strategies based on patient-specific physiological and therapeutic requirements, thereby supporting personalized treatment approaches [82]. The design of smart tablets and AI to design oral dosage forms are among the abilities being considered.

Of particular interest is the idea of a library of formulations that are AI-driven. Within this context, the AI algorithms trained on pharmacogenomic and clinical outcome data will be used to match databases of pre-formulated nanocarriers to the individual patient profiles. After assessing the patient, the AI will choose the most fitting formulation, which saves a lot of time on aligning with the therapeutic process [83]. This approach is especially relevant for treatment-resistant patients and elderly populations, who often show variable metabolic and therapeutic response profiles.

It is also being associated with AI tools with sophisticated manufacturing methods, including 3D printing or automated microfluidics, to print a custom dosage of oral medication on demand. This specifically holds promise in the creation of patient-specific fixed dose combinations, polypills and modified-release matrices adjusted to circadian requirements or co-morbidities [84].

In addition to formulation, AI continues to be applied to monitor treatment effectiveness and make changes to the dosage based on a combination of wearable and ingestible devices. Physiological parameters that a smart wearable sensor can monitor are heart rate variability, galvanic skin response, movements, sleep cycles, and even facial affect. Such data streams can be input into AI models, which have been trained to identify early signs of psychotic relapse or drug side effects, which allows for taking measures ahead of time [85].

Systems that involve ingestible sensor devices or digital pills have been considered as methods to ensure drug ingestion and adherence in psychiatry. It is important to note that such tools can be considered an integral part of a digital monitoring system rather than a standalone approach that will serve as a closed-loop management system [86]. Wearable sensors, mobile-based markers of behavior, sleep and activity monitoring, speech monitoring, electronic monitoring of medication events, and clinician-controlled dashboards might give us more data on adherence, relapse risks, and tolerability. Currently, there is a lack of research regarding the effectiveness of closed-loop dose adjustments in schizophrenia, and most studies need prospective validation [87].

These systems may support a semi-closed-loop model of care in which digital signals alert clinicians to possible non-adherence, relapse risk, or emerging adverse effects. However, autonomous dose modification remains premature in schizophrenia care. At the current stage, AI-generated alerts or dosing suggestions should be reviewed by clinicians and interpreted alongside symptom assessment, medication history, adverse-effect profile, and patient preference. The mobile applications can be integrated with these systems to give both patients and providers just-in-time behavioral prompts or alerts. Another significant benefit is real-time adherence monitoring [88]. Ingestible sensors such as etectRx and digital pills cleared under Abilify MyCite assist in confirming the dose intake and commanding AI models which imitate and adjust dose according to missed doses or fluctuating pharmacokinetics.

The behavioral and environmental data with biological metrics are now being integrated into AI systems. Passive indicators of the state of mind are being tracked by smartphone-based geolocation data, patterns of social media usage, frequency of speech, and digital interaction [89]. The relapse prediction based on a week of multimodal data with AI models trained on such data reached 88 percent sensitivity. These devices are especially helpful in the outpatient environment where close clinical observation is restricted.

Notably, AI-driven systems have the capability of assisting the recalibration of doses when there is a missed dose or when there is the development of side effects. In case a patient fails to take two doses in a row or displays indicators of metabolic side effects, which include rapid weight gain or increased resting glucose, the system is capable of automatically calculating compensatory dosing or the need for clinical follow-up [90]. As shown in Figure 3, AI-based feedback loops utilize sustained inputs of wearable and ingestible items. These systems, coupled with the simulations of the digital twins, enable real-time adaptive therapeutic and adjusting the profile depending on the changing physiological and behavioral characteristics of a patient.

One of the most sophisticated uses of AI in personalized medicine is the concept of the digital twin, which refers to a continually refined digital replica of a specific patient. For schizophrenia management, a digital twin would need to integrate multimodal variables that describe the current state of the patient, biological predisposition, medication administration, changes in behavior, and treatment response. Potential input variables might comprise demographic information, age at disease onset, duration of illness, symptom ratings, past relapses, hospital admission details, exposure to antipsychotics, compliance history, previous side effects, pharmacogenetic factors such as CYP2D6, CYP3A4, and CYP1A2 genotypes, levels of medication in the blood, metabolism, neuroimaging characteristics, electrophysiology, sleep/activity patterns, speech attributes, and behavioral signals collected by smartphones or wearables. For digital twin development, multimodal inputs may include relatively stable variables such as genomic data, periodically updated clinical or neuroimaging data, and frequently updated digital biomarkers from wearable, ingestible, or smartphone-based technologies [91].

For digital twin modeling to provide meaningful information for the treatment process, its validation should go beyond just evaluating the model itself. The following aspects should be considered as validation criteria: sensitivity and specificity for predicting disease relapse or non-responsiveness, area under the ROC curve for classification tasks, comparison of predicted vs. observed risk through calibration curves, positive and negative predictive values in external cohorts, and clinical validity assessment via decision-curve analysis [92]. For pharmacokinetics or optimal dose findings, mean prediction error, root mean square error, bias, precision, and the agreement between predicted and observed drug concentrations in plasma should be provided [89].

In schizophrenia, digital twins are being trained using data from longitudinal studies, neuroimaging repositories, pharmacogenomics datasets, wearable sensor feeds, and clinical trial outcomes. Digital twin model based on 1,000 schizophrenia patients simulates the outcomes of three different oral antipsychotic regimens. The model achieved 82% accuracy in predicting optimal regimen-patient matches and flagged metabolic concerns in high-risk profiles [92].

They are now being simulated to bring co-treatment situations such as antipsychotics with mood stabilizers, antidiabetics, or nootropics. In Mayo Clinic, three adjunctive therapy combinations were simulated using a digital twin to compare them in 200 patients [93]. The twin-predicted optimal regimen matched observed real-world results in 74% of the cases, and therefore, has high translational potential.

Optimization of clinical trials is also being tried with digital twins. Virtual controls made using digital twin models can lower the costs of a trial, time, and ethical overheads of using placebo arms. The regulatory agencies, such as the FDA and EMA, have developed investigative frameworks for validating digital twin models in the adaptive trial designs. This may transform the trial methods in psychiatry by their use in dose-ranging, safety testing and individual risk stratification [94, 95].

In the future, the combination of digital twins and formulation libraries and real-time monitoring systems will allow moving towards a dynamic, responsive therapeutic ecosystem. These systems may be able to produce intervention results depending on new either behavioral or physiological inputs, and prompt automatic changes in formulation or dosing [96]. With this system, schizophrenia care would be changed from reactive crisis management to the proactive precision psychiatry that is data-driven.

Nevertheless, several limitations exist concerning the use of AI-supported formulation design and pharmacokinetic prediction. The ability of AI algorithms to predict accurately is significantly influenced by the quality and quantity of information used during training. In nanomedicines, existing datasets may not always be sufficient or homogeneous since they are produced from distinct experimental setups. Hence, AI models built based on small or heterogeneous datasets may have high internal validity but weak external validity. Moreover, most of these models cannot yet be fully transparent, thus hindering their adoption by formulators, clinicians, and regulators. Hence, AI should only be used as a decision-making tool but not an alternative to empirical experiments. It can save time and effort in the development of formulations and help determine probable components of drug formulations and rationalize dose customization.

Reproducibility and generalizability remain among the most important challenges for AI models in schizophrenia care. Most ML models are trained on data that represents narrow geographic/institutional populations and hence, when implemented in different real-life environments, result in performance differences [98]. This training data heterogeneity is one of the reasons why the models are not robust to different clinical subtypes, ethnicities, and environmental factors. The problem is especially decisive in such a sphere as psychiatry, where the manifestation of symptoms and the reaction to treatment is extremely individual.

Furthermore, a large number of AI models are limited to proof-of-concept or preclinical level. Very few have been subjected to intensive external validation or prospective testing by randomized clinical trial. The clinical implementation is also limited by infrastructural factors, including the problem of interoperability of wearable devices, ingestible sensors, and the EHR of hospitals [99]. While the real-time patient monitoring device data stream integration into clinical workflows is technically complex and resource-intensive.

Scalability is also complicated by the absence of standardized protocols on the AI-enhanced oral drug formulation. Nanocarrier systems are normally associated with manufacturing flaws in terms of particle size distribution, surface charge, and encapsulation efficiency. These inconsistencies are a great hindrance to regulatory permission and mass manufacturing [100]. The technology of the AI-assisted formulation design has not yet reached a level of current good manufacturing practice (cGMP) standards, which restricts industrial translation. Also, AI implementation into the formulation process must balance datasets in formulation chemistry, pharmacokinetics, and patient-specific variables a multifactorial problem still unsolved completely [101].

Clinically, adoption has low levels of digital literacy in healthcare providers on AI assisted tools. A significant number of clinicians do not believe in model accuracy and are not usually keen on leaving therapeutic choices to systems that are viewed as black boxes. Moreover, the vast majority of AI-generated results cannot be explained, and a clinician may not find it easy to judge the model predetermination [102]. These are the obstacles to the adoption of trust and uptake by psychiatrists and pharmacists as the gatekeepers to schizophrenia management.

AI application in psychiatry presents special ethical challenges, especially in terms of data management, transparency of models, and bias possibilities. The use of wearable technology, ingestible sensors, and mobile health applications produces continuous and granular data feeds that contain physiological, behavioral, and even geolocation data. Though such data have immense clinical value, collection and storage of such data are a great threat to privacy and autonomy. In schizophrenic patients who already might be paranoid or distrustful of such surveillance may worsen the symptoms or reduce the level of adherence to treatment [103].

The processes of informed consent should be modified to handle the dynamism and evolving aspects of AI monitoring. Formal consent forms are not always adequate to present dynamic systems which learn and adapt as they are used [104]. The patients should be provided with the option to refuse to be collected in particular forms of data or have their data not be utilized to create an algorithm. The patient identities should be safeguarded with the help of transparent data stewardship schemes, such as federated learning, and differential privacy [105].

Another issue that is burning is algorithmic bias. AI systems trained using biased or non-representative data might strengthen or increase healthcare inequalities. As an example, NLP speech analysis models can be inefficient with speech from underrepresented language groups, which results in incorrect diagnoses or late intervention [106]. A 2023 study found that an NLP tool, which was applied to determine the risk of psychosis, discovered that its false negative rate was 25% higher in non-English speakers than in native English speakers. The solution to these disparities is a deliberate data diversification throughout training, and periodic performance auditing between demographical subgroups [107].

Prediction of false positives poses a particularly salient ethical challenge in prodromal and high-risk groups. AI-powered systems that wrongly predict someone as having a high risk of psychosis can create distressing experiences for those involved, stigmatization, unnecessary clinical monitoring, and even premature pharmacological treatment. The relevance of this problem lies in the fact that only some people in the clinically high-risk group eventually develop psychosis. Thus, AI-based prodromal detection must not be used on its own as a classification system. It should be employed as an aid in the diagnosis process together with clinical evaluation, monitoring over time, family history, deterioration in functioning, and personal preference of the patient.

Elucidation is one of the significant obstacles to the ethical incorporation of AI tools. Deep learning models and especially multimodal data fusion models tend to generate results that are not easily understandable by clinicians and patients. It does not make therapeutic decisions easy to defend without a clear understanding of the contribution of the input variables to the outputs. Such XAI methods as attention mapping, SHAP (Shapley additive explanations), and decision tree approximations have to be developed and made standard to use in clinical psychiatry [108]. Thorough model reporting and post hoc interpretability are required to make AI usage in schizophrenia care responsible and accountable.

In order to get the best out of AI-powered oral therapeutics, a multi-faceted research agenda should be undertaken. To begin with, datasets on which AI models are being trained must be increased to cover a wide range of patient populations, symptom clusters, and environmental factors. This can be enabled by federated learning platforms, which allow multiple institutions to train shared models without directly exchanging sensitive patient-level data [109]. Global healthcare settings will have to be cross-validated to be able to define generalizability. In addition, AI generated results ought to be compared with those of expert clinicians to determine practical utility.

Secondly, regulatory engagement should also be proactive. Regulatory authorities such as FDA, EMA, and CDSCO (Central Drugs Standard Control Organization) ought to work with academic and industry stakeholders to establish approval routes for AI-formulated medicine and decision support systems [110]. Cross-validation across global healthcare settings will be necessary to establish generalizability. Moreover, AI outputs should be benchmarked against expert clinician decisions to assess real-world utility.

Third, most ML models are trained on data representing narrow geographic or institutional populations and, therefore, may exhibit performance differences when implemented in diverse real-world environments [111]. The existing models of software as a medical device (SaMD) need to be broadened to encompass more hybrid platforms with formulation modeling, therapeutic monitoring, and self-adjusting doses. Oral therapeutics with AI augmentation may also benefit from evaluation within controlled regulatory frameworks before broader clinical implementation [112].

Fourth, the digital infrastructure needs to be improved so that it can enable real-time monitoring and the implementation of AI in psychiatry. It entails the combination of wearable sensors, ingestible devices, and digital twin models with the hospital EHRs. The presence of interoperability standards must be created to make data exchange between devices and AI platforms seamless [113, 114]. Simultaneously, clinicians would have to be trained in the fields of AI interpretation and digital literacy, preferably via continuing medical education coursework and curricula in psychiatry and pharmacy studies.

Lastly, ethical management should become a part of the research and implementation process. The use of AI tools should be tested in terms of biasness, transparency, and patient safety by independent ethics boards prior to their widespread use. It is also important that there is engagement with the people. Caregivers and patients must co-design AI systems to make sure that their worries on privacy, agency, and trust are appropriately taken into consideration at the initial stage [114]. Figure 4 presents a strategic roadmap of AI-integrated schizophrenia therapeutics to help inform the future direction of translation. It charts the milestones that are crucial such as standardization of data and federation of learning up to regulatory validation and clinical deployment that are necessary in the adoption of the systems.

Even though the integration of AI with nanodelivery systems represents an excellent solution for delivering antipsychotic drugs through precision oral delivery, its translational capacity is contingent upon the extent to which the computational algorithmic models represent the actual release behavior of nanocarrier systems. One important drawback in terms of the predictive power of such computational models is the possibility that some of the data on the release patterns are derived from in vitro setups that are not standardized. The problem is that release experiments in nanocarrier studies often vary greatly in their design and can include dialysis bag technique, modified Franz diffusion cell setup, USP (United States Pharmacopeia) dissolution method, or custom-made agitation systems. The parameters influencing the release pattern can involve the composition of the dissolving medium, pH regimen, number of enzymes, surfactant amount, speed of agitation, membrane type, frequency of sampling, and temperature [111].

A related limitation involves potential discrepancies between in vitro release characteristics and in vivo pharmacokinetic properties. With oral nanocarriers, the in vivo behavior of the drug does not solely depend on its release rate from the carrier, but is further affected by gastric retention, intestinal transit time, interaction with bile salts, diffusion across mucus layers, enzymatic degradation, absorption through the enterocytes, lymphatic delivery, penetration through the BBB, and first pass effect [97]. As such, formulations with an optimal in vitro release profile will not always deliver the desired profile of either plasma or brain concentrations over time. Using AI-generated dose recommendations that consider solely in vitro release kinetics without pharmacokinetic assessment could either over- or under-estimate exposure to therapy or dose dumping, among other things.

In order to mitigate this risk, a validation strategy for the development of future AI-assisted oral nanotherapeutics needs to be created based on a closed loop validation procedure involving AI predictions, standardized release testing in vitro, and pharmacokinetics in vivo. In this approach, the AI system would predict the composition and release pattern of the drug formulation, which would then be validated using standard release methodologies such as relevant USP dissolution apparatus or biorelevant dissolution medium tests [105]. The obtained results from the release experiments would need to be compared against pharmacokinetic parameters, including Cmax, Tmax, AUC, half-life, brain-to-plasma ratio, and individual variation in patients. A discrepancy between the predicted and experimentally observed drug release or pharmacokinetic profile would indicate the need for model refinement and retraining using newly generated experimental data to improve predictive accuracy [84, 113].